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Background
Standardization of allergen vaccines is mainly based on
In-House References (IHR), which are required for routine
quality control. Substitution of IHR batches can be a deli-
cate process that requires reproducibility of the reference
material and detailed in-vitro characterization and in-vivo
testing.
Objective
To develop a new IHR, of the Blomia tropicalis standar-
dized allergen extract and to predict its validity period
through an accelerated stability study.
Methods
Standardized allergen extract of Blomia tropicalis was
manufactured by BIOCEN (Cuba). The batch selected for
IHR was characterized by in-vitro allergenic activity com-
pared to the previous IHR, using ELISA-IgE-inhibition
assays, with a pool of sera from patients allergic to Blomia
tropicalis. Allergenic and protein composition was deter-
mined by Western-Blotting-IgE and SDS-PAGE. As final
criterion allergenic activity was measured by in-vivo Skin
Prick Test in allergic patients by parallel application of
three dilutions. Relative potency was calculated by the
method of parallel lines. The activity was expressed in Bio-
logical Units (BU), which is related to the skin reaction
size produced by Histamine 10 mg/mL. Stability was
assessed by means of an accelerated study at 4 tempera-
tures (-70°, 4°C, 37°C and 60°C) during one year, testing at
0, 3, 6, 9 and 12 months.
Results
The physical-chemical characterization of the new IHR,
complies with the limits established by national and
international guidelines. A good agreement was found
between the in-vivo and in-vitro, results for the aller-
genic potency: 100 453 UB (95%CI from 130 444 to 77
357), showing no significant difference with respect to
the previous IHR. Therefore, the new IHR is equivalent
to the later, regarding in-vitro and in-vivo allergenic
activity, protein and allergenic composition. The IHR
remained stable at -70°C, 4°C and 37°C for 12 months.
At 60°C, despite a change in cake appearance, the aller-
genic activity was kept during the first 6 months within
the specified limits.
Conclusions
A new IHR of Blomia tropicalis allergen vaccine was
developed, replacing the previous batch dating from
2006. It was certified for quality control use. The results
predicted stability at -70°C for more than 10 years, thus
assuring the reproducibility and quality of routine manu-
facturing batches.
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